DDInter644 DDInter1082
A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Rosoxacin
Enoxacin {u} (Compound) binds {v} (Gene) TOP2A
Enoxacin {u} (Compound) upregulates {v} (Gene) PRKCH
Enoxacin {u} (Compound) downregulates {v} (Gene) RNF167
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Insulin glargine
Enoxacin (Compound) resembles Levofloxacin (Compound)
Enoxacin (Compound) resembles Rosoxacin (Compound)
Enoxacin (Compound) binds TOP2A (Gene)
Enoxacin (Compound) upregulates PRKCH (Gene)
Enoxacin (Compound) downregulates RNF167 (Gene)
Enoxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Enoxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin
Enoxacin may lead to a major life threatening interaction when taken with Insulin glargine